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Zinc transporter 8 (ZnT8) is a major autoantigen and a predictive marker in type 1 diabetes (T1D). To investigate 
ZnT8-specific antibodies, a phage display library from T1D was constructed and single-chain antibodies against ZnT8 were 
screened and identified. Human T1D single-chain variable fragment (scFv) phage display library consists of approximately 
1108 clones. After four rounds of bio-panning, seven unique clones were positive by phage ELISA. Among them, C27 and 
C22, which demonstrated the highest affinity to ZnT8, were expressed in Escherichia coli Top10F’ and then purified by affin-
ity chromatography. C27 and C22 specifically bound ZnT8 N/C fusion protein and ZnT8 C terminal dimer with one 
Arg325Trp mutation. The specificity to human islet cells of these scFvs were further confirmed by immunohistochemistry. In 
conclusion, we have successfully constructed a T1D phage display antibody library and identified two ZnT8-specific scFv 
clones, C27 and C22. These ZnT8-specific scFvs are potential agents in immunodiagnostic and immunotherapy of T1D. 
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Zinc is an essential element for all cells and plays an im-
portant role in insulin secretion. Zinc transporter (ZnT) and 
Zrt/Irt-like protein (ZIP) are two main components that 
maintain zinc homeostasis in the body (Overbeck et al., 
2008). The proteins of ZnT family play a role as zinc ion 
diffusion facilitators, which allow diffusion of zinc ion 
across biological membrane. Among ZnT family members, 
Chimienti et al. first showed that ZnT8, encoded by the 
gene SLC30A8, was the most expressed transporter in hu-
man pancreas and further identified that ZnT8 was exclu-
sively expressed in secretory granules of islet β cells 
(Chimienti et al., 2004; Chimienti et al., 2006). The overex-
pression of ZnT8 in islet cells stimulates zinc accumulation 
and enhances glucose-stimulated insulin secretion compared 
with control cells (Chimienti et al., 2006). These findings 
showed that ZnT8 is essential for zinc accumulation and the 
storage, secretion, and the action of insulin.  
Type 1 diabetes (T1D) is an autoimmune disease result-
ing from the destruction of islet β cells by immune respons-
es. The immune cells attack a series of autoantigens ex-
pressed in β cells. These autoantigens were identified, in-
cluding insulin, 65-kD isoform of glutamic acid decarbox-
ylase (GAD), tyrosine phosphatase and ZnT8. Among them, 
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ZnT8 was observed to be one of the major autoantigens and 
a predictive marker in risk groups before onset of the dis-
ease. Wenzlau et al. followed the individuals from birth to 
T1D onset and they found that ZnT8 antibodies (ZnT8A) 
appeared as early as 2 years of age and showed increasing 
levels and prevalence persisting to disease onset (Wenzlau 
et al., 2009; Wenzlau et al., 2007). Some suggested a strong 
inverse relationship between the age of T1D onset and the 
prevalence of ZnT8A (Kawasaki, 2012). Our study demon-
strated that ZnT8 as a novel autoantigen containing many 
immunodominant epitopes, which were recognized in type 1 
diabetes patients (Xu et al., 2015). The detection of anti-
bodies and CD8+ T cells against ZnT8 is an important way 
for the prediction and diagnosis of T1D. Antigen-specific 
therapy which targets to ZnT8 could be a potential way in 
preventing and/or delaying the progression of T1D in the 
future (Dang et al., 2011).  
Antibody research has developed over a century. Kohler 
and Milstein first created B lymphocyte hybridoma tech-
nology in 1975 (Kohler and Milstein, 1975). On the one 
hand, the antibodies generated from mouse were immuno-
genic to human, they were easy to generate human an-
ti-mouse antibody (HAMA) (Hasholzner et al., 1997) and 
allergic reaction (Richter and Daquillard, 1980). On the 
other hand, such antibodies were macromolecules and were 
difficult to cross the membrane. So the applications of such 
antibodies have been limited in the field of disease treat-
ment. Now, some whole molecular antibodies against ZnT8 
have been produced through B lymphocyte hybridoma 
technology (Ustinova et al., 2013). But due to the disad-
vantages mentioned above, the applications of such anti-
bodies were limited.  
Since 1980s, phage display was established for the study 
of protein-protein and protein-DNA interaction (McCafferty 
et al., 1990). Now, phage display is a powerful technique 
for isolating specific antibodies against a given antigen. 
Among these whole molecular antibodies, scFv is only 1/6 
of the whole antibody; small molecular weight makes it 
possible to penetrate between blood vessels or tissue barri-
ers more easily. Other advantages of scFv are: more stable 
structure, shorter half-life, and with no constant fragment 
(Fc), which may cause the adverse impacts.  
Chimeric antigen receptors (CARs) are emerging as 
powerful tools for modified T cell specificity and function 
in immunotherapy (Brenner and Heslop, 2010), in which T 
cells are genetically engineered to express extracellular 
scFv antigen-binding domains fused to intracellular signal-
ing domains (Cheadle et al., 2014). CARs were applied in 
immunology and got some interesting results. Tregs ex-
pressing CARs against specific antigens have been tested 
and their functions have been verified in vitro and in vivo 
(Elinav et al., 2009; Fransson et al., 2012; MacDonald et al., 
2016), which provided a basis to develop the immunother-
apy for autoimmune disease by CAR-Treg.  
To further investigate and identify the ZnT8-specific an-
tibodies in T1D, we constructed a scFv phage display li-
brary of T1D and then isolated the positive clones against 
ZnT8 protein which may provide a novel way to immuno-
diagnosis or immunotherapy of T1D.  
RESULTS 
Production and identification of the recombinant ZnT8 
protein 
The ZnT8 N/C fusion construct (~550 bp) and the ZnT8 C 
terminal dimer construct (~650 bp) gene were amplified and 
successfully inserted into pcoldⅡvector (Figure 1). The 
inserted DNA was confirmed by sequencing.  
The estimated molecular weight of N/C fusion protein 
and C terminal dimer were about 20 kD and 25 kD respec-
tively. After purification, the protein showed distinct bands 
on SDS-PAGE corresponding to the expected size (Figure 
2). The results indicated that the recombinant proteins were 
successfully expressed and purified.  
The ELISA assay of the N/C fusion protein to the com-
mercial antibodies showed that the purified and denatured 
ZnT8 protein has bioactivity which confirmed that it could 
be used to screen ZnT8 specific antibodies (Figure 3).  
Construction of phage display scFv library from T1D 
patients’ peripheral blood 
There were 31 individuals among the 50 volunteers showed 
positive responses to ZnT8. After RT-PCR and overlapping 
PCR, scFv gene (~750 bp) was successfully assembled 
(Figure 4). After inserted scFv DNA fragments to the 
pcomb3XSS with Sfi I and transformed into E. coli XL1- 
Blue, a phage display library containing 1.0108 clones 
was successfully constructed. 
 
 
Figure 1  Construction of recombinant ZnT8 gene. N terminal (1–74 aa) 
and C terminal (268–369 aa) gene were amplified from the plasmid con-
taining full length of human ZnT8 (Slc30A8) ORF. N/C fusion gene was 
amplified by overlap-PCR. C terminal dimer gene was amplified from the 
plasmid donated by Barbara Davis Center. M, DNA ladder Marker; lane 1, 
N terminal PCR product amplified by primer ZF and LR, (~250 bp); lane 2, 
C terminal PCR product amplified by primer LF and CR, (~350 bp); lane 3, 
N/C fusion PCR product amplified by primer ZF and CR, (~550 bp); lane 4, 
C terminal dimer PCR product amplified by primer CF and CR, (~650 bp). 
688 Wu, Q., et al.   Sci China Life Sci   July (2016) Vol.59 No.7 
 
Figure 2  Purification and identification recombinant protein of ZnT8. 
Proteins were transferred onto PVDF after electrophoresis in 12% 
SDS-PAGE. HRP-conjugated anti-His antibody was used to detect the 
recombinant protein. A, Western blotting analyze of N/C fusion protein 
(lane 1, Protein before purification; lane 2, Protein after purification; lane 3, 
flow pass during purification). B, SDS-PAGE analyze of N/C fusion pro-
tein (M, protein ladder marker, lane 1, Protein before purification; lane 2, 
Protein after purification; lane 3, flow pass during purification). C, Western 
blotting analyze of C terminal dimer (lane 1, Protein before purification; 
lane 2, Protein after purification; lane 3, flow pass during purification). D, 
SDS-PAGE analyze of C terminal dimer protein (M, protein ladder marker, 
lane 1, Protein before purification; lane 2, Protein after purification; lane 3, 
flow pass during purification). The estimated molecular weight of N/C 
fusion protein was about 20 kD, The estimated molecular weight of C 
terminal dimer protein was about 25 kD. 
 
Figure 3  Binding ability of N/C fusion protein to ZnT8A measured by 
ELISA. ZnT8 N/C fusion protein was coated on the ELISA plate with the 
concentration varied from 1.6 μg well–1 to 0.1 μg well–1 by serial dilution. 
Commercial rabbit anti-human ZnT8A was used as primary antibody, 
HRP-conjugated anti-rabbit IgG was used as secondary antibody. Rabbit 
serum was used as negative control. 
 
Figure 4  Construction of scFv phage display library from T1D. Vλ, Vκ, 
VH gene were amplified by a group of human specific constant region 
primers. ScFv gene was amplified by overlap-PCR. M, Marker; lane 1, Vλ 
PCR product (~350 bp); lane 2, Vκ PCR product (~350 bp); lane 3, VH 
PCR product (~450 bp); lane 4, scFv PCR product (~800 bp).  
Production and identification of anti-ZnT8 scFv  
After four rounds of bio-panning, enrichment of high affin-
ity scFv was obtained. The titers of the eluted phages of 
each round of panning were showed in Table 1. A 32-fold 
increase in the ratio of outputted vs inputted phage titer, 
expressed as the enrichment factor, was observed from 
round 3 to round 4 (Table 1).  
ScFvs were selected from 160 randomly picked clones 
by phage ELISA. Among them, eleven clones showed high 
positivity and seven different scFvs were obtained (Figure 
5). They all contained ~750 bp scFv confirmed by DNA 
sequencing. The affinity of scFv C27 and C22 were the 
highest among these positive clones. Therefore, we chose 
them as our major scFvs for further experiments. 
After expression and purification, both C27 and C22 
showed a single band with the expected size (~30 kD) (Fig-
ure 6). 
Bioactivity of anti-ZnT8 scFv 
As shown in Figure 7, ZnT8 N/C fusion protein showed a 
band ~20 kD with C27 and C22 scFv, which is the predicted 
molecular weight.  
The affinity assay showed that both C27 and C22 scFv 
bound to N/C fusion protein with high affinity, the kD (M) 
was 5.39710−8 and 5.95310−8 respectively (Figure 8).  
Table 1  Enrichment of phage display library from ZnT8 N/C fusion proteina) 
Round Iuputted Outputted Yield (%) Enrichment (Yield n/Yield n–1) 
1 1×1013 4×105 4×10–6 — 
2 2.5×1012 8×105 3.2×10–5 8.0 
3 1.8×1012 1.4×106 7.8×10–5 2.4 
4 1×1012 2.5×107 2.5×10–3 32 
a) Yield (%)=outputted phages (pfu)×100/inputted phages (pfu). 
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Figure 5  Binding ability of scFv antibodies to ZnT8 N/C fusion protein 
by phage-ELISA. The 11 clones shown in the figure were selected based 
on high positive binding to recombinant ZnT8 protein. 
 
Figure 6  Purification and identification of scFv. Proteins were trans-
ferred onto PVDF after electrophoresis in 12% SDS-PAGE. 
HRP-conjugated anti-His antibody was used to detect the recombinant 
protein. A, SDS-PAGE analyze of scFv (M, Protein ladder marker; lane 1, 
scFv-C27 before purification; lane 2, purified scFv-C27; lane 3, flow pass 
during scFv-C27 purification; lane 4, scFv-C22 before purification; lane 5, 
purified scFv-C22; lane 6, flow pass during scFv-C22 purification). B, 
Western blotting analyze of scFv (M, Protein ladder marker; lane 1, 
scFv-C27 before purification; lane 2, purified scFv-C27; lane 3, flow pass 
during scFv-C27 purification; lane 4, scFv-C22 before purification; lane 5, 
purified scFv-C22; lane 6, flow pass during scFv-C22 purification).  
 
Figure 7  Binding ability of scFv to ZnT8 N/C fusion protein by western 
blotting analyze. ZnT8 N/C fusion protein was transferred onto PVDF after 
electrophoresis in 12% SDS-PAGE, scFv was used as primary antibody, 
HRP-conjugated anti-HA antibody was used as second antibody. The bac-
teria transformed with negative plasmid were used as negative control. A, 
lane 1, N/C fusion protein detected with scFv-C27; lane 2, negative control. 
B, lane 1, N/C fusion protein detected with scFv-C22; lane 2, negative 
control. 
As shown in Figure 9, the binding capacity of serial di-
luted scFv to the C terminal dimer decreased with the dilu-
tion ratio increased, which indicated the renatured scFvs 
could bind to ZnT8 in a concentration dependent manner. 
As shown in Figure 10, these two scFvs were specific to 
human islet cells. 
DISCUSSION 
In this study, we first constructed a T1D phage display scFv 
library containing 1.0108 clones which could be applied 
for antibody screening. We recruited 50 newly diagnosed 
T1D patients to ensure the diversity and the wide represent-
ativeness of the antibody library. From our phage display 
library, we can screen all antibodies of T1D, which is valu-
able for further studies of antibodies in T1D. To our 
knowledge, the T1D scFv phage display library has neither 
been established nor been used to screen T1D related anti-
bodies before.  
As described in some articles, ZnT8 antigen, encoded by 
the gene SLC30A8, is a major autoantigen in T1D 
(Kawasaki, 2012). SLC30A8 gene is located on chromo-
some 8 at the position q24.11 in human. It contains eight 
exons, spanning 37 kb, and encoding ZnT8 protein contain-
ing 369 amino acids, which has six transmembrane helixes 
as the other ZnT proteins (Chimienti et al., 2004; Seve et 
al., 2004; Weijers, 2010). The autoantibodies against ZnT8 
play an important role in the onset and development of 
T1D. The N terminal (1–74 aa) and C terminal (268–369 
aa) proteins of ZnT8, located in the extracellular part in 
insulin secreting vesicles, contain many important epitopes 
recognized by autoantibodies (Skarstrand et al., 2015; 
Skarstrand et al., 2013; Wenzlau et al., 2007). As ZnT8 
might be one of the key players in mediating both insulin 
secretion and β cell mass in T1D, a thorough understanding 
of the molecular function of ZnT8A can help us design an 
immunotherapy to cure T1D. To ensure the diversity of the 
screened scFv, we chose ZnT8 N/C fusion protein for 
bio-panning. Since previous studies showed that principal 
epitopes targeted by ZnT8A were influenced by a single 
amino acid at position 325 encoded as arginine or trypto-
phan in T1D, the ZnT8 C terminal dimer with Arg325Trp 
mutation protein has been proved to possess both specificity 
and sensitivity to detect ZnT8A (Kawasaki et al., 2014; 
Kawasaki et al., 2008; Wenzlau et al., 2008). We identified 
the specificity of scFvs through ZnT8 C terminal dimer with 
Arg325Trp mutation. Our results showed that both 
scFv-C27 and scFv-C22 well recognized C terminal dimer 
protein, which indicated that these two clones of scFv iso-
lated in this study were specific to ZnT8 protein. The im-
munohistochemistry results further confirmed scFv-C27 and 
scFv-C22 were specific to human islet cells. 
In conclusion, we successfully constructed a T1D phage 
display scFv library, screened and identified ZnT8 specific 
scFvs, scFv-C27 and scFv-C22. These two clones of scFv 
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Figure 8  Affinity test of scFv to ZnT8 N/C fusion protein. A, Affinity of scFv-C27 to N/C fusion protein; B, Affinity of scFv-C22 to N/C fusion protein. 
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Figure 9  Binding capacity of scFv to C terminal dimer protein measured 
by ELISA.  C terminal dimer protein was coated on the ELISA plate with 
0.5 μg well–1. The scFvs used as primary antibody were diluted from 1:10 
to 1:20480 by serial dilution. HRP-conjugated anti-HA antibody was used 
as secondary antibody. 
 
Figure 10  Immunohistochemical reaction to ZnT8 in the human pancreas. 
ScFv were used as primary antibody, Rabbit anti-HA tag was used as se-
cond antibody, HRP-conjugated anti-Rabbit antibody was used as third 
antibody. A, Islet cells detected by C27. B, Islet cells detected by C22. 
Row 1, ×40 magnification; row 2, ×200 magnification. 
demonstrating high affinity and specificity will enable us to 
address the questions relating to the role of ZnT8 in T1D 
pathogenesis, and also provide the basis for developing sat-
isfactory diagnostics and therapeutics, such as CAR-Treg, 
which could be used to treat or alleviate the disease. 
MATERIALS AND METHODS 
Cloning and expression of recombinant ZnT8 
The ZnT8 N/C fusion protein construct (1–74aa, 268–369 
aa) was made by combining a N terminal (1–74 aa) PCR 
product generated with the forward primer ZF and a reverse 
primer LR and a C terminal (268–369 aa) PCR product 
generated with a forward primer LF and reverse primer CR 
(Table 2) from a plasmid contains full length of human 
ZnT8 (Slc30A8) ORF (Sino Biological Inc , HG11621-M). 
The products were gel purified, mixed and reamplified with 
the ZF and CR primers to generate an N/C fusion sequence. 
The ZnT8 C terminal dimer with one Arg325Trp muta-
tion was amplified using the forward primer CF and the 
reverse primer CR (Table 2) from the plasmid donated by 
Barbara Davis Center for Childhood Diabetes, University of 
Colorado at Denver and Health Sciences Center, USA. The 
C terminal dimer with one Arg325Trp mutation consisted 
two of C terminal, first 268–369 had Arg at position 325 
and the second Trp at 325. The two C terminals were linked 
by the sequence encoding for a short peptide (Gu et al., 
2011).  
The target gene was cloned into pcoldⅡ vector (Biovec-
tor pcoldⅡ) with Sac Ι and Xba Ι (Takara) and then trans-
formed into E. coli BL21 (DE3). The positive clones were 
selected and identified by DNA sequencing.  
The verified clones were cultured in LB medium with 
100 μg mL–1 Ampicillin at 37°C with further induction by 1 
mmol L–1 isopropyl-β-D-thiogalactoside (IPTG) for 24h at 
15°C when the optical density 600 (A600) reached 1.0. The 
bacteria can be preserved at –80°C after centrifugation at 
10,000×g for 15 min at 4°C.  
Protein purification 
The bacteria were resuspended in binding buffer (Table 3) 
and sonicated on ice by ultrasonic homogenizer. The super-
natant was filtrated with hydrophilic polyethersulfone 
membrane (0.22 mm, Millipore) after centrifugation at 
10,000×g for 30 min. The supernatant was stored at 4°C for 
further experiments. A HisTrap™ chromatography was 
used to purify the protein. The target protein was then eluted 
by elution buffer (Table 3). The eluted protein was dialyzed 
in dialysis buffer (Table 3) supplemented with 4 mol L–1 urea 
at 4°C and renew half of the liquid volume with dialysis 
buffer (Table 3) every 4 to 6 hours until the urea concentra-
tion below to 0.125 mol L–1.  
Construction of phage display scFv library from T1D 
patients’ peripheral blood 
PBMC were isolated from 50 newly diagnosed T1D patients 
according to the World Health Organization criteria. Serum 
ZnT8A levels were analyzed by immunoprecipitated radio-
activity as described earlier (Gu et al., 2011). All samples 
were collected with appropriate informed consent. We am-
plified VH and VL genes by RT-PCR using a group of spe-
cific constant region primers (Barbas et al., 2004). After 
spliced the scFv fragments generated by overlapping PCR, 
we ligated them into pComb3XSS phagemid. Then we in-
troduced the ligations into competent E. coli XL1-Blue by 
electroporation. The library was rescued and amplified by 
VCSM13 helper phage.
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Table 2  List of primers for the construction of the recombinant ZnT8 genea) 
Primer Sequence 





a) The primers ZF and LR are for the cloning of ZnT8 N terminal gene; the primers LF and CR are for the cloning of ZnT8 C terminal gene; the primers 
ZF and CR are for the cloning of ZnT8 N/C fusion gene; the primers CF and CR are for the cloning of ZnT8 C terminal dimer gene 
Table 3  List of buffers 
Buffer Buffer preparation(–L) 
Binding buffer NaH2PO4·2H2O 1.56 g, Na2HPO4·12H2O 3.58 g, NaCl 29.2 g, Imidazole 1.36 g, Urea 480.5 g (pH=7.5) 
Elution buffer NaH2PO4·2H2O 1.56 g, Na2HPO4·12H2O 3.58 g, NaCl 29.2 g, Imidazole 34 g, Urea 480.5 g (pH=7.5) 
Dialysis buffer NaH2PO4·2H2O 1.56 g, Na2HPO4·12H2O 3.58 g, NaCl 29.2 g, Imidazole 1.36 g (pH=7.5) 
Blocking buffer 5%Milk in PBS 
 
Panning and expression of anti-ZnT8 scFv  
The purified ZnT8 N/C fusion protein was coated onto 
ELISA plates for phage bio-panning. The screening proce-
dures and bacteria culture as well as transformation were 
operated as described elsewhere (Zhang et al., 2013). After 
four rounds of selection, E. coli XL1-Blue infected with 
phage were plated on agar plates and incubated overnight at 
37°C. Single bacterial colonies were picked and tested by 
phage-ELISA. The positive colonies were sequenced and 
analyzed through compared with the human immunoglobu-
lin sequences (IMGT Database) (Ehrenmann et al., 2010; 
Lefranc et al., 2015). 
Positive scFv-phagemids were extracted from E. coli 
XL1-Blue colonies and transformed into non-suppressor E. 
coli Top10F’. The verified clones were cultured in SB me-
dium with 100 μg mL–1 Ampicillin and 20 mmol L–1 MgCl2 
at 37°C for 8 h and then induced by 1 mmol L–1 IPTG for 
24 h at 37°C. The bacteria were preserved at –80°C after 
centrifugation at 10,000×g for 15 min at 4°C. 
SDS-PAGE and Western blotting  
To identify recombinant ZnT8 proteins and scFvs, separated 
proteins were transferred onto polyvinylidene fluoride 
(PVDF) membrane (Millipore) after electrophoresis in 12% 
SDS-PAGE. After blocked the membranes by blocking 
buffer for 2 h (Table 3), horseradish peroxidase (HRP)- 
conjugated anti-His antibody was added (1:4000) and incu-
bated for 1 h. The 0.05% PBST was used in washing pro-
cedure three times for 15 min between every two steps. 
Protein bands were visualized using ECL buffer (Millipore, 
WBKLS0500). 
To identify the binding ability of scFv to the ZnT8 N/C 
fusion protein, the scFv was used as primary antibody and 
the HRP-conjugated goat anti-HA (Genscript) was used as 
second antibody. The bacteria transformed with negative 
plasmid were used as negative control. 
Affinity test of anti-ZnT8 scFvs  
The affinity of scFv to ZnT8 N/C fusion protein was tested 
using BiacoreX100 at Suzhou BioTop Technical Service 
Co.,Ltd. 
ELISA assay 
The bioactivity of ZnT8 N/C fusion protein was detected by 
commercial ZnT8A (Abbiotec). N/C fusion protein was 
coated onto ELISA plates with different concentration range 
from 0.1 μg to 1.6 μg per well and incubated overnight at 
4°C. Each well was blocked with blocking buffer (Table 3) 
at 4°C overnight. Blocked wells were briefly rinsed with 
0.05% PBST and incubated of commercial ZnT8A with 
1:500 dilutions in blocking buffer and incubation at 37°C 
for 2 h. Rabbit serum were used as negative control. Un-
bound antibodies were removed by washing 3 times with 
0.05% PBST. HRP-conjugated goat anti-Rabbit were added 
with 1:2000 diluted in blocking buffer (Table 3) and incu-
bation at 37°C for 2 h. Wells were washed four times prior 
to color development. 
To identify the binding ability of scFv to ZnT8, we coat-
ed the C terminal dimer protein onto ELISA plates with 0.5 
μg per well and incubated overnight at 4°C. Each well was 
blocked with blocking buffer (Table 3) at 4°C overnight. 
Then incubated scFv antibodies doubling diluted from 1:10 
to 1:20480 in blocking buffer at 37°C for 2 h. ScFv 4F5 
(Zhang et al., 2013) produced in our lab was used as nega-
tive control. Unbound antibodies were removed by washing 
3 times with 0.05% PBST. HRP-conjugated goat anti-HA 
were added with 1:2000 dilution in blocking buffer (Table 3) 
and incubation at 37°C for 2 h. Wells were washed four 
times prior to color development. 
Immunohistochemical analysis 
The function of the scFv was tested by immunohistochem-
istry. Human pancreas paraffin sections (4  μm) were depar-
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affinized and antigen retrieval performed in 10  m mol L–1 
citrate buffer (pH 6.0) for 15 min at 121°C. After blocking 
with 3% bovine serum albumin (BSA), the sections were 
incubated with scFv at 4°C overnight and the with rabbit 
anti-HA antibody at 4°C for 12 h. For immunoperoxidase 
detection, HRP-conjugated anti-rabbit antibody was used. 
Images were captured using confocal microscopy. 
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